Aprea Therapeutics, Inc. $APRE

By Microcap Ledger desk · CIK 0001781983

Facts as of Oct 11, 2026, 08:18 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Capital Market
Sector: Pharmaceutical Preparations
Headquarters: Doylestown, PA
Fiscal year end: December 31
Shares outstanding: 12,591,136 [10-Q 2026-08-12]
as of 2026-08-12

Sources: [10-K 2026-03-16]

What the company doesAI summary of filing

Aprea Therapeutics is a clinical-stage precision oncology company developing small molecule inhibitors targeting cancer-related genetic mutations. The company's lead programs are APR-1051, a WEE1 inhibitor in Phase 1 clinical trials for solid tumors with specific genetic mutations, and ATRN-119, an ATR inhibitor that has completed dose escalation in a Phase 1/2a trial. The company also has a preclinical DYRK1 inhibitor program. Aprea is pre-revenue and does not generate product sales; it funds operations through financing and develops its candidates using contract manufacturers for clinical supply and planned future commercial production. [10-K 2026-03-16]

Segments: APR-1051 (WEE1 inhibitor), ATRN-119 (ATR inhibitor), APR-1602 (DYRK1 inhibitor), APR-246 (p53 reactivator)

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	—	−$6.88M	−$6.04M	$41.23M	[10-Q 2026-08-12]
FY ended Dec 2025	—	−$12.60M	−$12.89M	$14.60M	[10-K 2026-03-16]
FY ended Dec 2024	—	−$12.96M	−$13.56M	$22.85M	[10-K 2026-03-16]

Quarterly cash burn: −$3.02M

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-11-07	5,434,903	[10-Q 2024-11-07]
2025-03-25	5,491,953	[10-K 2025-03-25]
2025-05-13	5,531,373	[10-Q 2025-05-14]
2025-08-11	5,825,261	[10-Q 2025-08-12]
2025-11-11	6,310,673	[10-Q 2025-11-12]
2026-03-16	11,452,452	[10-K 2026-03-16]
2026-05-13	12,382,776	[10-Q 2026-05-13]
2026-08-12	12,591,136	[10-Q 2026-08-12]

Shelf registration: S-3 filed 2026-04-22; declared effective 2026-04-29 [S-3 2026-04-22]

Listing status

Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-23. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2026-07-23	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-07-23]
2026-01-23	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-01-23]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-06-16	Grissinger Michael	grant	3,135	—	[4 2026-06-17]
2026-06-16	Gruia Gabriela	grant	3,135	—	[4 2026-06-17]
2026-06-16	Peters Richard	grant	3,135	—	[4 2026-06-17]
2026-06-16	Henneman John B Iii	grant	3,135	—	[4 2026-06-17]
2026-06-16	Bizzari Jean-Pierre	grant	3,135	—	[4 2026-06-17]
2026-06-16	Duey Marc	grant	3,135	—	[4 2026-06-17]
2026-06-16	Pamukcu Rifat	grant	3,135	—	[4 2026-06-17]
2026-06-16	Seizinger Bernd R.	grant	3,135	—	[4 2026-06-17]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-08-28	8-K	Other events
2026-08-13	13G/A	Beneficial ownership report (5%+ holder)
2026-08-12	10-Q	Quarterly report
2026-08-12	8-K	Results of operations; Other events
2026-07-23	8-K	Listing notice or transfer
2026-06-17	8-K	Shareholder vote results
2026-05-15	13G	Beneficial ownership report (5%+ holder)
2026-05-15	424B7	Prospectus or prospectus supplement
2026-05-13	10-Q	Quarterly report
2026-05-13	8-K	Results of operations; Other events
2026-04-30	DEF 14A	Proxy statement
2026-04-29	424B3	Prospectus or prospectus supplement

Facts as of Oct 11, 2026, 08:18 AM UTC. Small caps move fast; check the latest filings.